Evidence map›Paper›PMID 42552605›Full record

ArticleImmunology2026

Metabolic Profiling of Circulating and Tumour-Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients.

Hugo Brouque, Kareem Mahdy, Stephane Mouret, Sylvain Henry, Camille Niveau, Mélanie Cettour-Cave, Martin Pelosse, Florence de Fraipont, Julie Charles, Andrei Turtoi and 2 more

Abstract read
In one paragraph

Article in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hugo BrouqueInstitute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes, Grenoble, France.
Kareem MahdyInstitute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes, Grenoble, France.
Stephane MouretDermatology, Allergology & Photobiology Department, CHU Grenoble Alpes, Univ. Grenoble Alpes, Grenoble, France.ORCID https://orcid.org/0000-0003-3880-973X
Sylvain HenryPlatform for Translational Oncometabolomics, Biocampus, CNRS, INSERM, Université de Montpellier, Montpellier, France.ORCID https://orcid.org/0000-0003-3460-8324
Camille NiveauInstitute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes, Grenoble, France.
Mélanie Cettour-CaveInstitute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes, Grenoble, France.
Martin PelosseEuropean Molecular Biology Laboratory, Grenoble, France.
Florence de FraipontMedical Unit of Molecular Genetic (Hereditary Diseases and Oncology), Grenoble University Hospital, Grenoble, France.ORCID https://orcid.org/0000-0001-9594-6584
Julie CharlesDermatology, Allergology & Photobiology Department, CHU Grenoble Alpes, Univ. Grenoble Alpes, Grenoble, France.ORCID https://orcid.org/0000-0003-4667-6009
Andrei TurtoiPlatform for Translational Oncometabolomics, Biocampus, CNRS, INSERM, Université de Montpellier, Montpellier, France.ORCID https://orcid.org/0000-0003-3813-6635
Philippe SaasInstitute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes, Grenoble, France.ORCID https://orcid.org/0000-0002-8857-9939
Caroline AspordInstitute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes, Grenoble, France.ORCID https://orcid.org/0000-0002-4979-7044

Funding

Agence Nationale de la Recherche ANR-11-LABX-0021Etablissement Français du Sang (EFS) AuRAFondation Bristol Myers Squibb (BMS)GEFLUCLigue Contre le CancerSociete Française de Dermatologie et de Pathologie Sexuellement TransmissibleUniversité Grenoble Alpes (UGA)
6 · The paper itself

Abstract

Metabolism is critical for immune cell functions. Tumours shape their microenvironment to render it metabolically hostile for infiltrating immune cells. While targeting immunometabolism emerges as a promising way to reinvigorate anticancer immunity, a deeper understanding of the metabolic disturbances of immune cells is needed. Here, we explored how the metabolic status of T cells governs immune skewing from circulating and tumour-infiltrating CD4

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEnergy MetabolismLymphocytes, Tumor-InfiltratingMelanomaMetabolomeMetabolomicsHumansMetabolic ReprogrammingTumor MicroenvironmentimmunometabolismmelanomametabolomicsSCENITHT cells

Identifiers

PMID42552605
PMCPMC13636174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.